On March 15, Salarius Pharmaceuticals Inc. (SLRX) finally rebounded in the after-hours following its continued downfall after its latest earnings. The company had declared its
Salarius Pharmaceuticals, Inc. (SLRX) is a leading late-stage biotherapeutics firm engaged in developing cancer therapeutics for oncology patients. The lead pipeline candidate of the company
On February 25, Salaruis Pharmaceuticals Inc. (SLRX) stock’s bullish momentum escalated in the after-hours as it added a further 10.03%. It seems investors are buying
Salarius Pharmaceuticals, Inc. (SLRX) stock rebounded in the after-hours on the news of dosing milestone achievement in its ongoing trial. On December 29, the company
This weekend, the U.S. government is packaging millions of doses of the coronavirus vaccine from Pfizer and BioNTech for distribution to places around the country,
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.